Tech Company Financing Transactions
Aardvark Therapeutics Funding Round
On 5/9/2024, Aardvark Therapeutics raised $85 million in Series C funding from Decheng Capital, Cantor Fitzgerald and Cormorant Asset Management.
Transaction Overview
Company Name
Announced On
5/9/2024
Transaction Type
Venture Equity
Amount
$85,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the proceeds from the financing to (1) complete the clinical trials required for regulatory approval of its lead asset, ARD-101, for the treatment of hyperphagia in patients with Prader-Willi Syndrome, (2) demonstrate ARD-101's complementary mechanism of action to the current GLP-1 therapies in the treatment of obesity and (3) advance other pipeline programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
12707 High Bluff Dr. 200
San Diego, CA 92130-2035
USA
San Diego, CA 92130-2035
USA
Phone
Website
Email Address
Overview
Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders. Aardvark Therapeutics was founded by Tien Lee in 2017.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tien Lee
Chief Financial Officer
Nelson Sun
Chief Marketing Officer
Andreas Niethammer
Chief Scientific Officer
Zhenhuan Zheng
VP - Operations
Anjuli Timmer
Browse more venture capital transactions:
Prev: 5/9/2024: Uxuy venture capital transaction
Next: 5/9/2024: FleetPulse venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs